dbACP: A Comprehensive Database of Anti-Cancer Peptides

304 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00007 Citropin modified peptide-3 GLFAVIKKVASVIGGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 1 µM
dbacp00016 Citropin modified peptide-5 GLFDVIKAVASVIGGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 100 µM
dbacp00025 Citropin modified peptide-7 GLFDVIKKVAAVIGGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp00104 Citropin modified peptide-11 GLFDVIKKVASVIKGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp00113 Citropin modified peptide-13 GLFDVIKKVASVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp00122 Citropin modified peptide-14 GLFDVIAKVASVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp00156 Citropin modified peptide-15 GLFAVIKKVASVIKGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp00189 Citropin modified peptide-16 GLFAVIKKVASVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp00223 Citropin modified peptide-17 GLFAVIKKVAAVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp00258 Citropin modified peptide-18 GLFAVIKKVAAVIRRL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : >10 µM
dbacp00267 Citropin modified peptide-19 GLFAVIKKVAKVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp00276 Citropin modified peptide-22 GLFKVIKKVASVIGGL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : >10 µM
dbacp00298 Citropin modified peptide-23 GLFKVIKKVAKVIKKL Amphibian skin secretions Penetration and disruption of the membrane Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : >10 µM
dbacp00814 AAD (or Aa-Pri1) MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYPSDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYWECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN Purified from chestnut mushroom Apoptosis inducing MTT/MTS assay HepG-2 Liver cancer At 2.5 µM concentration,decrease in cell vibility: 35%
dbacp00981 Adenoregulin GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV South American frog, Giant leaf frog Cell membrane disintegration LDH leakage assay DU-145 Liver cancer GI50 : 0.91 ± 0.04 µM
dbacp01192 Ascaphin-8 [T16A] GFKDLLKGAAKALVKAVLF Synthetic construct Not specified Not specified Not found Liver cancer Not found
dbacp02379 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 91.8% cell viability at 12.5 µM
dbacp02380 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 84.1% cell viability at 25 µM
dbacp02381 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 76.3% cell viability at 50 µM
dbacp02382 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 71.5 % cell viability at 75 µM
dbacp02383 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 54.2 % cell viability at 100 µM
dbacp02384 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 87.3 % cell viability at 25 µM
dbacp02385 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 75.6 % cell viability at 50 µM
dbacp02386 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 62.8 % cell viability at 75 µM
dbacp02387 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 54.3 % cell viability at 100 µM
dbacp02388 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 48.6 % cell viability at 100 µM
dbacp02389 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 72.1 % cell viability at 12.5 µM
dbacp02390 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 63.3 % cell viability at 25 µM
dbacp02391 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 49.7 % cell viability at 50 µM
dbacp02392 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 41.1 % cell viability at 75 µM
dbacp02393 Ceropin MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG House fly Apoptosis inducing Trypan blue assay BEL-7402 Liver cancer 35.2 % cell viability at 100 µM
dbacp02494 Citropin 1.1 GLFDVIKKVASVIGGL Amphibian skin secretions Penetration and disruption of the membranes Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp02498 Citropin 1.1 GLFDVIKKVASVIGGL Blue mountains tree frog Penetration and disruption of the membranes Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp02505 Citropin 1.1D glfdvikkvasviggl Amphibian skin secretions Penetration and disruption of the membranes Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : 5 M
dbacp02837 Emericellipsin A PQAAIVASG **Emericellopsis alkaline** VKPM F1428, Alkalophile, extremophile Disrupt cell membrane structures; Apoptosis MTT assay Hep G2 Liver cancer EC50 : 2.8 µM
dbacp03060 GGN6 FLPLLAGLAANFLPTIICKISYKC Skin of a Korean frog, wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : 4.91 µg/ml
dbacp03283 Hc-CATH KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL Green paddy frog Not specified MTT assay HepG2 Liver cancer 4.70% cell death at 200 µg/ml
dbacp03285 Hc-CATH KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL Green paddy frog Not specified MTT assay PC-3 Liver cancer 3.63% cell death at 200 µg/ml
dbacp03287 Hc-CATH KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL Green paddy frog Not specified MTT assay L929 Liver cancer 1.30% cell death at 200 µg/ml
dbacp03355 Hymenochirin-1B KLSPETKDNLKKVLKGAIKGAIVAKMV Zaire dwarf clawed frog Membrane disruption and cell lysis Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay HepG2 Liver cancer LC50 : 22.5 ± 1.4 μM
dbacp03385 Interferon gamma (IFN-gamma) MKYTSYILAFQLCVVLGSLGCYCQDPYVKEAENLKKYFNAGDSDVADNGTLFLDILRTWREEGDRKIMQSQIISFYFKLFKNFKDNQSIQKSMETIKEDMNVKFFNSNKRKQDDFERLTNYSVNDLNVQRKAIHELIQVMAELSPAPKIGKRKRSQTLFRGRRASQ White-tufted ear marmoset Immunomodulatory activity Bioassay, EMCV assay, Luciferase assay Huh7 Liver cancer Activity: 2 – 5 U/pg
dbacp03386 Interferon gamma (IFN-gamma) MKYTSYILAFQLCVVLGSLGCYCQDPYVKEAENLKKYFNAGDSDVADNGTLFLDILRTWREEGDRKIMQSQIISFYFKLFKNFKDNQSIQKSMETIKEDMNVKFFNSNKRKQDDFERLTNYSVNDLNVQRKAIHELIQVMAELSPAPKIGKRKRSQTLFRGRRASQ White-tufted ear marmoset Immunomodulatory activity Bioassay, EMCV assay, Luciferase assay A549 Liver cancer Activity: 2 – 5 U/pg
dbacp03447 Interferon gamma (IFN-gamma) MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGDSDVADNGTLFLDILRTWREEGDRKIMQSQIISFYFKLFKNFKDNQSIQKSMETIKEDMNVKFFNSNKRKQDDFERLTNYSVKDLNVQRKAIHELIQVMAELSPAPKIGKRKRSQTLFRGRRASQ Moustached tamarin Immunomodulatory activity Bioassay, EMCV assay, Luciferase assay Huh7, A549 Liver cancer Activity: 2 – 5 U/pg
dbacp04319 LvHemB1 DVNFLLHKIYGNIRY Marine invertebrates Inducing apoptosis MTT assay HeLa Liver cancer Not found
dbacp04323 LvHemB1 DVNFLLHKIYGNIRY Marine invertebrates Inducing apoptosis MTT assay EC109 Liver cancer Not found
dbacp04327 LvHemB1 DVNFLLHKIYGNIRY Marine invertebrates Inducing apoptosis MTT assay HepG2 Liver cancer Not found
dbacp04331 LvHemB1 DVNFLLHKIYGNIRY Marine invertebrates Inducing apoptosis MTT assay EJ Liver cancer Not found
dbacp04335 LvHemB1 DVNFLLHKIYGNIRY Marine invertebrates Inducing apoptosis MTT assay THLE-3 Liver cancer Not found
dbacp04594 Mauriporin MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR Fat-tailed scorpion Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis MTT assay, Lactate dehydrogenase (LDH) Release assay HepG2 Human liver cancer IC50 : 27.9 μM - 283.3 μM
dbacp05001 NuBCP-9 (DR8) FSRSLHSLLRRRRRRRR Not found Inducing apoptosis XTT assat HepG2 Liver cancer IC50 : 9.10 μM
dbacp05433 Peptide XT-7 GLLGPLLKIAAKVGSNLL Western clawed frog Membrane disruption and cell lysis Lactate dehydrogenase assay HepG2 Liver cancer LD50 : 20 µM
dbacp05711 PTP1 LLAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : >100 µg/ml
dbacp05716 PTP2 FAGLAANFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : >100 µg/ml
dbacp05721 PTP4 FLKLLKKLAAKFLPTIICKISYKC Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : 18.18 µg/ml
dbacp05726 PTP5 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer Not found
dbacp05731 PTP6 FLKLLKKLAAKLF Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : 15.07 µg/ml
dbacp05736 PTP7 FLGALFKALSKLL Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : 5.4 µg/ml
dbacp05741 PTP8 FLKLLAGLLKNFA Skin of a Korean frog, Wrinkled frog Induce apoptosis MTT/MTS assay Hep3B Liver cancer IC50 : 30.79 µg/ml
dbacp05940 Retro LGGIVSAVKKIVDFLG Amphibian skin secretions Penetration and disruption of the membranes Sulforhodamine B assay Liver tumor celline Liver cancer IC50 : >10 µM
dbacp05944 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay SMMC-7721 Liver cancer 70.39 Inhibition ratio at 50 µg/ml
dbacp05946 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HepG-2 Liver cancer 60.22 Inhibition ratio at 50 µg/ml
dbacp05949 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HL7702 Liver cancer 36.25 Inhibition ratio at 50 µg/ml
dbacp05953 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay SMMC-7721 Liver cancer 86.175 Inhibition ratio at 50 µg/ml
dbacp05955 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HepG-2 Liver cancer 73.07 Inhibition ratio at 50 µg/ml
dbacp05958 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HL7702 Liver cancer 38.13 Inhibition ratio at 50 µg/ml
dbacp06117 SK84 SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK Fruit fly Cell membrane disintegration MTS/PES colorimetric assay HepG2 Liver cancer IC50 : 92 μM
dbacp06119 SK84 SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK Fruit fly Cell membrane disintegration MTS/PES colorimetric assay MCF-7 Liver cancer IC50 : 50 μM
dbacp06121 SK84 SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK Fruit fly Cell membrane disintegration MTS/PES colorimetric assay THP-1 Liver cancer IC50 : 35 μM
dbacp06124 SK84 SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK Fruit fly Destroying the cell membranes Cell proliferation assay HepG2 Liver cancer MIC : 4 – 8 mM
dbacp06130 Smp24 ILQDIWNGIKNLF-NH Israeli gold scorpion Disrupt the structure and function of cell membranes ATP release assay HepG3 Liver cancer MIC : 94.8% (±7.5) at 512 μg/ml
dbacp06131 Smp24 IWSFLIKAATKLLPSLFGGGKKDS Venom, Israeli Gold Scorpion Disrupt the structure and function of cell membranes ATP release assay HepG2 Liver cancer MIC : 32 μg/ml
dbacp06132 Smp43 GVWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS Venom, Israeli Gold Scorpion Disrupt the structure and function of cell membranes ATP release assay HepG2 Liver cancer MIC : 512 μg/ml
dbacp06188 T Peptide TKPRKTKPRKTKPRKTKPR Tuftsin derivative Immune regulation MTT/MTS assay HepG-2 Liver cancer 69.6% maximum inhibitory rate at 8 mg/kg
dbacp06249 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay SMMC-7721 Liver cancer 52.77 inhibition ratio at 50 µg/ml
dbacp06251 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay HepG-2 Liver cancer 50.90 inhibition ratio at 50 µg/ml
dbacp06254 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay HL7702 Liver cancer 37.22 inhibition ratio at 50 µg/ml
dbacp06258 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay SMMC-7721 Liver cancer 59.37 inhibition ratio at 50 µg/ml
dbacp06260 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay HepG-2 Liver cancer 55.98 inhibition ratio at 50 µg/ml
dbacp06263 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay HL7702 Liver cancer 37.00 inhibition ratio at 50 µg/ml
dbacp06408 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 39.0% Cytotoxic at 0.1 µg/ml
dbacp06409 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 20.8% Cytotoxic at 1 µg/ml
dbacp06410 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 33.8% Cytotoxic at 10 µg/ml
dbacp06411 Tyroserleutide YSL Synthetic Peptide Necrosis; Immune regulation MTT/MTS assay BEL-7402 Liver cancer 35.6% Cytotoxic at 100 µg/ml
dbacp06417 U3 NGSIPATWASL Date palm Cell proliferation inhibition MTT/MTS assay Hep G2 Liver cancer IC50 : 561 μM
dbacp06420 U7 NCSIHGDIPAY Date palm Cell proliferation inhibition MTT/MTS assay Hep G2 Liver cancer IC50 : 523 μM
dbacp06754 37-mer peptide TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC Synthetic Apoptosis inducing MTT assay SNU-449 Liver Cancer IC50 = 76.4 ± 0.6015 μM
dbacp06755 37-mer peptide TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 33.65 ± 1.09 μM
dbacp06852 WP1 RLLRLMRLRMLLRM Derived from RLL peptide Apoptosis inducing Cell Viability assay Huh-7 Liver Cancer IC50 = 43.74 ± 5.4 μM
dbacp06853 WP1 RLLRLMRLRMLLRM Derived from RLL peptide Apoptosis inducing Cell Viability assay HepG-2 Liver Cancer IC50 = 52.23 ± 0.9 μM
dbacp06856 WP2 RLLRLLRLRRLLRL Derived from RLL peptide Apoptosis inducing Cell Viability assay Huh-7 Liver Cancer IC50 = 28.12 ± 1.5 μM
dbacp06857 WP2 RLLRLLRLRRLLRL Derived from RLL peptide Apoptosis inducing Cell Viability assay HepG-2 Liver Cancer IC50 = 34.05 ± 0.53 μM
dbacp06865 Pep-1-Phor21 CGEMGWVRCKFAKFAKKFAKFAKKFAKFAK Hybrid peptide PEP1 and Phor 21 Not available AlamarBlue assay LNCaP Liver Cancer IC50 = 55.13 ± 13.56 µM
dbacp06904 LFcin17–30 FKCRRWQWRMKKLG Lectoferrin Peptide Apoptosis inducing MTT assay HepG-2 Liver Cancer cell viability ~ 50% at 1 µM
dbacp06906 LFampin265–284 DLIWKLLSKAQEKFGKNKSR Lectoferrin Peptide Apoptosis inducing MTT assay HepG-2 Liver Cancer cell viability ~ 50% at 1 µM
dbacp06908 LFchimera FKCRRWQWRMKKLG-K-RSKNKGFKEQAKSLLKWILD Synthetic - Lectoferrin chimera Apoptosis inducing MTT assay HepG-2 Liver Cancer cell viability ~ 44% at 10 µM
dbacp06924 #2(D33-N52) RRRRRRRRGGDRDYKKFWAGLQGLTIYFYN STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-B
dbacp06926 #5(D93-F112) RRRRRRRRGGDQEIKFKVETLECREMWKGF STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-B
dbacp06927 #6(M108-L127) RRRRRRRRGGMWKGFILTVVELRVPTDLTL STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-B
dbacp06929 2A(F39-Q58) RRRRRRRRGGFWAGLQGLTIYFYNSNRDFQ STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-C
dbacp06930 2C(Q44-Q58) RRRRRRRRGGQGLTIYFYNSNRDFQ STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-C
dbacp06931 2D(Q44-R55) RRRRRRRRGGQGLTIYFYNSNR STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-C
dbacp06932 2D2(Q44-Y51) RRRRRRRRGGQGLTIYFY STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-C
dbacp06933 2D3(G45-N52) RRRRRRRRGGGLTIYFYN STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-C
dbacp06934 2D5(G45-Y51) RRRRRRRRGGGLTIYFY STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer IC50 = 19.4 μM
dbacp06935 6E(V116-M135) RRRRRRRRGGVVELRVPTDLTLLPGHLYMM STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-D
dbacp06936 6F (I113-P122) RRRRRRRRGGILTVVELRVP STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-D
dbacp06937 TAT-2D5 GRKKRRQRRRPPQGGLTIYFY STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-G
dbacp06938 HTLV-II-Rex-2D5 TRRQRTRRARRNRGGLTIYFY STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-G
dbacp06939 FHV-2D5 RRRRNRTRRNRRRVRGGLTIYFY STAP-2 PH domain–derived peptide Inhibition of cell signalling CellTiter-Glo assay DU-145 Liver Cancer Graph figure 1-G
dbacp06943 HTDT-6-2-3-2 GPLGAGP Enteromorpha prolifera Apoptosis inducing CCK-8 assay HepG-2 Liver Cancer IC50 = 1.2564 ± 0.0548 mg/mL
dbacp06945 LJP-6 FKEHGY Laminaria japonica Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 3.06 ± 0.31 mM
dbacp06946 LJP-1 EGFHL Laminaria japonica Inhibition of cell signalling MTT assay Huh-7 Liver Cancer IC50 = 0.48 ± 0.05 mM
dbacp06947 LJP-1 EGFHL Laminaria japonica Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 0.45 ± 0.05 mM
dbacp06948 LJP-1 EGFHL Laminaria japonica Inhibition of cell signalling MTT assay H-22 Liver Cancer IC50 = 0.36 ± 0.03 mM
dbacp06949 LJP-8 FSHTYV Laminaria japonica Inhibition of cell signalling MTT assay Huh-7 Liver Cancer IC50 = 0.44 ± 0.04 mM
dbacp06950 LJP-8 FSHTYV Laminaria japonica Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 0.63 ± 0.05 mM
dbacp06951 LJP-8 FSHTYV Laminaria japonica Inhibition of cell signalling MTT assay H-22 Liver Cancer IC50 = 0.76 ± 0.08 mM
dbacp06952 LJP-2 LWEHSH Laminaria japonica Inhibition of cell signalling MTT assay Huh-7 Liver Cancer IC50 = 2.25 ± 0.22 mM
dbacp06953 LJP-2 LWEHSH Laminaria japonica Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 1.71 ± 0.13 mM
dbacp06954 LJP-2 LWEHSH Laminaria japonica Inhibition of cell signalling MTT assay H-22 Liver Cancer IC50 = 0.62 ± 0.05 mM
dbacp06955 LJP-3 FSHRGH Laminaria japonica Inhibition of cell signalling MTT assay Huh-7 Liver Cancer IC50 = 1.42 ± 0.12 mM
dbacp06956 LJP-3 FSHRGH Laminaria japonica Inhibition of cell signalling MTT assay H-22 Liver Cancer IC50 = 1.70 ± 0.15 mM
dbacp06957 LJP-5 FSTHGG Laminaria japonica Inhibition of cell signalling MTT assay Huh-7 Liver Cancer IC50 = 2.44 ± 0.22 mM
dbacp06958 LJP-5 FSTHGG Laminaria japonica Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 2.78 ± 0.26 mM
dbacp06959 LJP-5 FSTHGG Laminaria japonica Inhibition of cell signalling MTT assay H-22 Liver Cancer IC50 = 1.49 ± 0.13 mM
dbacp06960 LJP-7 HAGYSWA Laminaria japonica Inhibition of cell signalling MTT assay Huh-7 Liver Cancer IC50 = 2.53 ± 0.24 mM
dbacp06961 LJP-7 HAGYSWA Laminaria japonica Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 1.66 ± 0.11 mM
dbacp06962 LJP-7 HAGYSWA Laminaria japonica Inhibition of cell signalling MTT assay H-22 Liver Cancer IC50 = 1.44 ± 0.12 mM
dbacp06963 LJP-9 FEHSG Laminaria japonica Inhibition of cell signalling MTT assay Huh-7 Liver Cancer IC50 = 0.53 ± 0.05 mM
dbacp06964 LJP-9 FEHSG Laminaria japonica Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 0.69 ± 0.08 mM
dbacp06965 LJP-9 FEHSG Laminaria japonica Inhibition of cell signalling MTT assay H-22 Liver Cancer IC50 = 0.51 ± 0.07 mM
dbacp06966 LJP-10 HASWEH Laminaria japonica Inhibition of cell signalling MTT assay Huh-7 Liver Cancer IC50 = 3.52 ± 0.35 mM
dbacp06967 LJP-10 HASWEH Laminaria japonica Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 2.69 ± 0.22 mM
dbacp06968 LJP-10 HASWEH Laminaria japonica Inhibition of cell signalling MTT assay H-22 Liver Cancer IC50 = 3.53 ± 0.34 mM
dbacp06969 LJP-11 YEHSHG Laminaria japonica Inhibition of cell signalling MTT assay Huh-7 Liver Cancer IC50 = 0.49 ± 0.05 mM
dbacp06970 LJP-11 YEHSHG Laminaria japonica Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 0.61 ± 0.07 mM
dbacp06971 LJP-11 YEHSHG Laminaria japonica Inhibition of cell signalling MTT assay H-22 Liver Cancer IC50 = 0.70 ± 0.07 mM
dbacp06972 LJP-12 TFKHG Laminaria japonica Inhibition of cell signalling MTT assay Huh-7 Liver Cancer IC50 = 0.41 ± 0.04 mM
dbacp06973 LJP-12 TFKHG Laminaria japonica Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 0.60 ± 0.08 mM
dbacp06974 LJP-12 TFKHG Laminaria japonica Inhibition of cell signalling MTT assay H-22 Liver Cancer IC50 = 0.72 ± 0.05 mM
dbacp06977 C16-E4Y EEEEY Synthetic Inhibition of cell signalling WST-8 assay HepG-2 Liver Cancer 50 % cell viability at 0.05 wt %
dbacp06981 Ponericin-W1 (11-25), At1 KLLPSVVGLFKKKKQ Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 >100 µM
dbacp06983 Ponericin-W1 (11-25) [P4K KLLKKVVKLFKKKKK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 >100 µM
dbacp06985 Ponericin-W1 (11-25) [P4K KLLKKVVKLFKKLLK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 2.2 µM
dbacp06987 At4 KLLKKLLKLLKKLLK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 2.5 µM
dbacp06989 At5 KIIKKIIKIIKKIIK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 1.5 µM
dbacp06991 At6 KVVKKVVKVVKKVVK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 70.8 µM
dbacp06993 At7 KIIKKIKKKIKKIIK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 8.8 µM
dbacp06995 At8 KLLKKLKKKLKKLLK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 8.9 µM
dbacp06997 At9 KVVKKVKKKVKKVVK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 51.7 µM
dbacp06999 At10 IKKIIKIIKKIIKKI Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 3.2 µM
dbacp07001 At11 IIIKKIKKKIKKIII Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 7.6 µM
dbacp07003 At12 KIIIKIKKKIKIIIK Synthetic Apoptosis inducing MTT assay HepG-2 Liver Cancer IC50 = 13.4 µM
dbacp07004 Rapeseed peptide NDGNQPL extracted from rapeseed protein Inhibition of cell signalling MTT assay HepG-2 Liver Cancer IC50 = 1.56 mmol/L
dbacp07005 Rapeseed peptide NDGNQPL extracted from rapeseed protein Inhibition of cell signalling Apoptosis assay HepG-2 Liver Cancer 28.39 ± 0.80% apoptosis rate at 0.5 mmol/L
dbacp07024 [G10a]-SHa FLSGIVGMLaKLF Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay HepG-2 Liver Cancer IC50 = 31.63 ± 1.56 µM
dbacp07031 [G10a]2-SHa FLSGIVGMLaKLFKFLKaLMFLSGIVG Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay HepG-2 Liver Cancer IC50 = 14.31 ± 1.37 µM
dbacp07038 [G10a]3-SHa FLSGIVGMLaKLFFLSGIVGMLaKLFFLSGIVGMLaKLFKK Analog of temporin SHa Dendrimerization enhances stability, selectivity, anticancer efficacy Resazurin dye assay HepG-2 Liver Cancer IC50 = 5.49 ± 0.37 µM
dbacp07103 rScyreprocin MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH Recombinant product of Scyreprocin Membrane disruption triggers ROS-mediated apoptosis MTS assay HepG-2 Liver Cancer IC50 = 441.01 µM
dbacp07112 Galaxamide (N-Me-L)L(N-Me-L)LL Galaxaura filamentosa Cell-cycle arrest induces apoptosis MTT assay HepG-2 Liver Cancer IC50 = 5.20 ± 0.52 µg/ml
dbacp07118 Z-1 L(N-Me-L)LPL Synthetic Cell-cycle arrest induces apoptosis MTT assay HepG-2 Liver Cancer IC50 = 7.57 ± 0.17 µg/ml
dbacp07258 trans-Phakellistatin 18 trans(P)PIPYPIF Synthetic Not Available MTT assay HepG-2 Liver Cancer IC50 = 67.5 ± 2.938 µM
dbacp07357 GA - 7 Structure given in figure Synthetic (glycyrrhetinic acid (GA)-based peptides) Apoptosis induction, Bax/p53/caspase activation MTT assay HepG-2 Liver Cancer IC50 = 3.30 ± 0.1 µg/mL
dbacp07401 NMTP-5 zffygwyggmekllrggrgerppr Not Available NRP1/MDM2 inhibition induces apoptosis MTT assay SK-HEP-1 Liver Cancer IC50 = 53.84 ± 4.35 µM
dbacp07406 LvHemB1 DVNFLLHKIYGNIRY hemocyanin of Litopenaeus vannamei Mitochondrial targeting induces apoptosis MTS assay HepG-2 Liver Cancer 44.2% apoptotic cells at 50 μg/mL
dbacp07472 MzDef MSSSNCANVCQTENFPGGECKAEGATRKCFCKNC Zea mays L. Disulfide-stabilized peptide disrupts pathogens MTT assay HepG-2 Liver Cancer IC50 ~ 22 µg/mL
dbacp07477 (LLKK)4 linear peptide LLKKLLKKLLKKLLKK Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay SK-HEP-1 Liver Cancer Cell Viability (%) ~ 14.1 ± 0.8 at 30 µg/mL
dbacp07481 2-arm branched peptide [LLKKLLKK]2kC Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay SK-HEP-1 Liver Cancer Cell Viability (%) ~ 85.7 ± 4.3 at 30 µg/mL
dbacp07485 4-arm branched peptide {[LLKKLLKK]2kC}2 Synthetic Apoptosis, drug-resistance reversal, tumor suppression MTT assay SK-HEP-1 Liver Cancer Cell Viability (%) ~ 31.7 ± 5.1 at 30 µg/mL
dbacp07553 macrocyclic pyridoheptapeptide derivative 1a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 6.615 ± 0.353 μM
dbacp07555 macrocyclic pyridoheptapeptide derivative 1b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 8.724 ± 0.474 μM
dbacp07557 macrocyclic pyridoheptapeptide derivative 1c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 17.011 ± 0.965 μM
dbacp07558 macrocyclic pyridoheptapeptide derivative 2a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 17.513 ± 0.876 μM
dbacp07560 macrocyclic pyridoheptapeptide derivative 2b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 18.681 ± 0.988 μM
dbacp07562 macrocyclic pyridoheptapeptide derivative 2c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 19.318 ± 1.057 μM
dbacp07564 macrocyclic pyridoheptapeptide derivative 3a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 8.063 ± 0.863 μM
dbacp07566 macrocyclic pyridoheptapeptide derivative 3b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 9.66 ± 0.792 μM
dbacp07568 macrocyclic pyridoheptapeptide derivative 3c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 16.957 ± 1.161 μM
dbacp07570 macrocyclic pyridoheptapeptide derivative 4a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 7.31 ± 0.595 μM
dbacp07572 macrocyclic pyridoheptapeptide derivative 4b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 7.166 ± 0.892 μM
dbacp07574 macrocyclic pyridoheptapeptide derivative 4c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 9.631 ± 0.932 μM
dbacp07575 macrocyclic pyridoheptapeptide derivative 5a Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 7.117 ± 0.790 μM
dbacp07576 macrocyclic pyridoheptapeptide derivative 5b Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 7.088 ± 0.784 μM
dbacp07577 macrocyclic pyridoheptapeptide derivative 5c Structure given in Scheme 1 Synthetic Macrocyclic peptides disrupt cancer growth MTT assay HepG-2 Liver Cancer IC50 = 9.568 ± 1.139 μM
dbacp07668 Longicalycinin A linear analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.66 ± 0.0007 µg/ml
dbacp07670 Longicalycinin A linear analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 13.29% Cell death at 100 µg/ml
dbacp07672 Longicalycinin A Cyclic analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.2 ± 0.007 µg/ml
dbacp07674 Longicalycinin A Cyclic analogue 1 GYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 69.73% Cell death at 100 µg/ml
dbacp07676 Longicalycinin A linear analogue 2 LYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 8.76 ± 0.0035 µg/ml
dbacp07678 Longicalycinin A linear analogue 2 LYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 71.37% Cell death at 100 µg/ml
dbacp07680 Longicalycinin A FYPFG Dianthus superbus Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 13.52 µg/ml
dbacp07683 Longicalycinin A FYPFG Synthetic Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.45 ± 0.0042 µg/ml
dbacp07685 Longicalycinin A (Linear) FYPFG Synthetic Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.18 ± 0.0014 µg/ml
dbacp07687 Longicalycinin A linear analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.67 ± 0.0007 µg/ml
dbacp07689 Longicalycinin A linear analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 13.02% Cell death at 100 µg/ml
dbacp07691 Longicalycinin A cyclic analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.46 ± 0.0028 µg/ml
dbacp07693 Longicalycinin A cyclic analogue 14 PYFFL Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 70.69% Cell death at 100 µg/ml
dbacp07695 Longicalycinin A linear analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.77 ± 0.0007 µg/ml
dbacp07697 Longicalycinin A linear analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 82.33% Cell death at 100 µg/ml
dbacp07699 Longicalycinin A cyclic analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.5 ± 0.0056 µg/ml
dbacp07701 Longicalycinin A cyclic analogue 3 GYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 56.72% Cell death at 100 µg/ml
dbacp07703 Longicalycinin A linear analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.53 ± 0.0014 µg/ml
dbacp07705 Longicalycinin A linear analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 27.13% Cell death at 100 µg/ml
dbacp07707 Longicalycinin A cyclic analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.77 ± 0.007 µg/ml
dbacp07709 Longicalycinin A cyclic analogue 4 AYPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 71.1% Cell death at 100 µg/ml
dbacp07711 Longicalycinin A linear analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 8.99 ± 0.0014 µg/ml
dbacp07713 Longicalycinin A linear analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 76.72% Cell death at 100 µg/ml
dbacp07715 Longicalycinin A cyclic analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.45 ± 0.0056 µg/ml
dbacp07717 Longicalycinin A cyclic analogue 5 FSPFG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 41.37% Cell death at 100 µg/ml
dbacp07719 Longicalycinin A linear analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.98 ± 0.0014 µg/ml
dbacp07721 Longicalycinin A linear analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 38.64% Cell death at 100 µg/ml
dbacp07723 Longicalycinin A cyclic analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 17.34 ± 0.0014 µg/ml
dbacp07725 Longicalycinin A cyclic analogue 6 VYPIA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 51.79% Cell death at 100 µg/ml
dbacp07727 Longicalycinin A linear analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.6 ± 0.0007 µg/ml
dbacp07729 Longicalycinin A linear analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 82.33% Cell death at 100 µg/ml
dbacp07731 Longicalycinin A cyclic analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.21 ± 0.0056 µg/ml
dbacp07733 Longicalycinin A cyclic analogue 7 PYVFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 47.68% Cell death at 100 µg/ml
dbacp07735 Longicalycinin A linear analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.35 ± 0.0014 µg/ml
dbacp07737 Longicalycinin A linear analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 15.35% Cell death at 100 µg/ml
dbacp07739 Longicalycinin A cyclic analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.12 ± 0.0007 µg/ml
dbacp07741 Longicalycinin A cyclic analogue 8 FYPVG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 36.85% Cell death at 100 µg/ml
dbacp07743 Longicalycinin A linear analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.33 ± 0.0007 µg/ml
dbacp07745 Longicalycinin A linear analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 72.74% Cell death at 100 µg/ml
dbacp07747 Longicalycinin A cyclic analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.67 ± 0 µg/ml
dbacp07749 Longicalycinin A cyclic analogue 9 FYPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 73.98% Cell death at 100 µg/ml
dbacp07751 Longicalycinin A linear analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.5 ± 0.0014 µg/ml
dbacp07753 Longicalycinin A linear analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 76.72% Cell death at 100 µg/ml
dbacp07755 Longicalycinin A cyclic analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.28 ± 0 µg/ml
dbacp07757 Longicalycinin A cyclic analogue 10 FYPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 72.06% Cell death at 100 µg/ml
dbacp07759 Longicalycinin A linear analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.56 ± 0.0021 µg/ml
dbacp07761 Longicalycinin A linear analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 70.28% Cell death at 100 µg/ml
dbacp07763 Longicalycinin A cyclic analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.36 ± 0 µg/ml
dbacp07765 Longicalycinin A cyclic analogue 11 TVPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 72.06% Cell death at 100 µg/ml
dbacp07767 Longicalycinin A linear analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 11.32 ± 0.0014 µg/ml
dbacp07769 Longicalycinin A linear analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 12.06% Cell death at 100 µg/ml
dbacp07771 Longicalycinin A cyclic analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 12.37 ± 0.0014 µg/ml
dbacp07773 Longicalycinin A cyclic analogue 12 FYPFI Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 63.84% Cell death at 100 µg/ml
dbacp07775 Longicalycinin A cyclic analogue 15 PYGFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.33 ± 0 µg/ml
dbacp07777 Longicalycinin A cyclic analogue 15 PYGFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 52.33% Cell death at 100 µg/ml
dbacp07779 Longicalycinin A linear analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 11.1 ± 0.0007 µg/ml
dbacp07781 Longicalycinin A linear analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 15.76% Cell death at 100 µg/ml
dbacp07783 Longicalycinin A cyclic analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 12.1 ± 0.0007 µg/ml
dbacp07785 Longicalycinin A cyclic analogue 16 FTPFV Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 42.33% Cell death at 100 µg/ml
dbacp07787 Longicalycinin A linear analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.33 ± 0.0007 µg/ml
dbacp07789 Longicalycinin A linear analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 27.54% Cell death at 100 µg/ml
dbacp07791 Longicalycinin A cyclic analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.4 ± 0.0014 µg/ml
dbacp07793 Longicalycinin A cyclic analogue 17 FSPFA Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 74.53% Cell death at 100 µg/ml
dbacp07795 Longicalycinin A linear analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 10.33 ± 0.0007 µg/ml
dbacp07797 Longicalycinin A linear analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 15.55% Cell death at 100 µg/ml
dbacp07799 Longicalycinin A cyclic analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer IC50 = 9.68 ± 0.0014 µg/ml
dbacp07801 Longicalycinin A cyclic analogue 18 FSPAG Synthetic Analogue of Longicalycinin A Cyclization enhances apoptosis via lysosomes MTT assay HepG-2 Liver Cancer 46.58% Cell death at 100 µg/ml
dbacp07878 Fi-Histin1-21 SRSSRAGLQFPVGRIHRLLRK Fenneropenaeus indicus Membrane disruption and DNA binding XTT assay Hep-2 Liver Cancer IC50 = 31.274 ± 24.531 μM
dbacp07891 H-58 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 2.13 ± 0.07 μM
dbacp07894 H-57 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 2.13 ± 0.07 μM
dbacp07897 H-18 IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.61 ± 0.21 μM
dbacp07900 H-21 IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.50 ± 0.28 μM
dbacp07903 H-20 IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 4.93 ± 0.53 μM
dbacp07906 H-19 IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.64 ± 0.36 μM
dbacp07909 H-17 IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.64 ± 0.47 μM
dbacp07912 H-16 IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 3.14 ± 0.46 μM
dbacp07915 H-15 IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 2.20 ± 0.27 μM
dbacp07918 H-10 IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.50 ± 0.21 μM
dbacp07921 H-5 IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 2.82 ± 0.23 μM
dbacp07924 H-2 IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV Synthetic Cell entry, DNA damage, apoptosis. MTT assay HepG-2 Liver Cancer IC50 = 1.60 ± 0.24 μM
dbacp07929 B11 RIRDAIAHGYIVDKV Litopenaeus vannamei hemocyanin-derived peptide Mitochondrial dysfunction, caspase-dependent apoptosis MTS assay HepG-2 Liver Cancer Decreased cell viability by 23% at 50 μg/mL
dbacp07945 Emericellipsin A (3-MeP)-(AHMOD)-A-Aib-IV-beta-A-N-(2-Hydroxyethyl)-1,2-propanediamine Emericellopsis alkalina Membrane disruption, antifungal, antibacterial, anticancer MTT assay HepG-2 Liver Cancer EC50 = 2.8 uM
dbacp07959 Compound 2a Structure in scheme 1 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 20.37 ± 1.36 µM
dbacp07961 Compound 2b Structure in scheme 1 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 15.80 ± 1.66 µM
dbacp07962 Compound 2c Structure in scheme 1 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 35.52 ± 1.83 µM
dbacp07963 Compound 3a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 26.01 ± 2.35 µM
dbacp07965 Compound 3b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 13.54 ± 1.45 µM
dbacp07967 Compound 3c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 26.64 ± 1.85 µM
dbacp07968 Compound 4a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 11.59 ± 2.70 µM
dbacp07970 Compound 4b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 10.25 ± 2.20 µM
dbacp07972 Compound 4c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 18.84 ± 1.47 µM
dbacp07974 Compound 5a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 11.19 ± 1.95 µM
dbacp07976 Compound 5b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 10.09 ± 2.05 µM
dbacp07978 Compound 5c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 7.53 ± 1.33 µM
dbacp07980 Compound 6a Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 12.44 ± 1.3 µM
dbacp07982 Compound 6b Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 11.53 ± 1.70 µM
dbacp07983 Compound 6c Structure in scheme 2 Synthetic 5c inhibits cancer via kinase blockade Not Available HepG-2 Liver Cancer IC50 = 12.07 ± 1.68 µM
dbacp08047 R11-NLS-pep8 RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa NKp44 derived synthetic peptide NKp44-pep8 inhibits PCNA function PrestoBlue assay HepG-2 Liver Cancer ED50 = 5.9 μM
dbacp08051 MEL-Pep GIGAVLKKLTTGLKALISWIKRKRQQ Synthetic analog of Melittin MEL-pep disrupts membrane, inhibits P-gp CCK-8 assay BEL-7402/5-FU Liver Cancer IC50 = 4.36 μM
dbacp08059 TAT-327 RKKRRQRRREFLDCFQKF Peptide-327 Peptide 327 blocks Eps8–EGFR CCK-8 assay HepG-2 Liver Cancer EC50 = 68.52 ± 2.96 μM
dbacp08082 Peptide 3a YD Synthetic Inhibit COX-2 enzyme MTT assay HepG-2 Liver Cancer IC50 = 4.8 ± 0.12 µM
dbacp08084 Peptide 3b YD Synthetic Inhibit COX-2 enzyme MTT assay HepG-2 Liver Cancer IC50 = 62.3 ± 0.02 µM
dbacp08115 FR-15 FRRFFKWFRRFFKFF Synthetic Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HepG-2 Liver Cancer IC50 = 2.5 μM
dbacp08119 FR4P FRRPFKWFRRFFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HepG-2 Liver Cancer IC50 = 2.5 μM
dbacp08123 FR8P FRRFFKWPRRFFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HepG-2 Liver Cancer IC50 = 4.2 μM
dbacp08127 FR11P FRRFFKWFRRPFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HepG-2 Liver Cancer IC50 = 4.8 μM
dbacp08131 FR4,8P FRRPFKWPRRFFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HepG-2 Liver Cancer IC50 = 5 μM
dbacp08135 FR8,11P FRRFFKWPRRPFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HepG-2 Liver Cancer IC50 = 15 μM
dbacp08146 LfcinB-P13 KCRRWLKRMKKLG Synthetic analog of LFcinB LfcinB-P13 induces liver cancer apoptosis MTT assay SMMC-7721 Liver Cancer IC50 = 41.8 µg/ml
dbacp08253 Cecropin XJ APEPRWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK Larvae of Bombyx mori CecropinXJ induces apoptosis in HCC MTT assay Huh-7 Liver Cancer Cell viability = 50% at 50 µmol/l
dbacp08255 Tr1 Not Available Protein extraction from Spirulina platensis Not Available MTT assay HepG-2 Liver Cancer IC50 = 147.03 μg/mL
dbacp08257 Tr2 Not Available Protein extraction from Spirulina platensis Not Available MTT assay HepG-2 Liver Cancer IC50 = 36.42 μg/mL
dbacp08261 Tr4 Not Available Protein extraction from Spirulina platensis Not Available MTT assay HepG-2 Liver Cancer IC50 = 176.37 μg/mL
dbacp08263 HR HVLSRAPR Fraction identified from Tr1 Not Available MTT assay HepG-2 Liver Cancer 22% inhibition at 500 μg/mL
dbacp08268 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay HepG-2 Liver Cancer IC50 = 7.5 ± 1.2 μM
dbacp08269 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay Huh-7 Liver Cancer IC50 = 8.4 ± 1.1 μM
dbacp08297 DN1 ILGKIVKKLVSDF Synthetic Not Available MTT assay HepG-2 Liver Cancer 152.17 ± 7.73 μM
dbacp08298 DN4 ILGKIWKGIVSDF Synthetic Not Available MTT assay HepG-2 Liver Cancer 191.67 ± 12.02 μM
dbacp08421 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay HepG-2 Liver Cancer IC50 = 3.064 μM
dbacp08422 5-2C NYPQRPCRGDKGPDC Synthetic Not Available MTT assay Hep3B Liver Cancer IC50 = 0.7847 μM